Vector Biology JournalISSN: 2473-4810

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Severity assessment of single-dose oxford-astra zeneca vaccinated individuals infected with SARS CoV-2 in Southeast Bangladesh

Coronavirus disease (COVID-19) vaccination campaign is underway in several parts of the planet including Bangladesh but till to this point there’s
no available health data revealed among the vaccinated people. We conducted a cross-sectional study to assess the health status of 1st dose Oxford-
AstraZeneca vaccinated individuals infected with SARS CoV-2. Standard virological method real-time reverse transcriptase-polymerase chain
reaction (RT-qPCR) was performed to detect SARS-CoV-2 and different health parameters from vaccinated individuals were collected using prestructured
questionnaires during infection period. A total of 6146 suspected samples were tested and 1752 were found positive for SARS-CoV-2,
of them 200 individuals were identified who received 1st dose of COVID-19 vaccine. Among the vaccinated individuals, 165 (82.5%) patients were
not hospitalized and 177 (88.5%) did not show any respiratory difficulties. Only 8% of patients required extra oxygen support and 199 (99.5%)
individuals didn’t desiderate any intensive care unit (ICU) interference. Overall, oxygen saturation was recorded around 96.8% and respiratory
difficulties did not extend more than 5 days during the infection period. Within the vaccinated COVID-19 positive individuals 113 (56.5%) and
111(55.5%) persons have normal physiological taste and smell. Surprisingly, 129 (64.5%) individuals carrying different comorbidity where high
blood pressure 36 (27.9%) and diabetes 32 (24.8%) were found more prevalent. However, the significant finding of the present study was 199
(99.5%) vaccinated individuals survived with good health conditions and became negative with subsequent RT-qPCR test. The results of this study
expound that administration of 1st dose Oxford-AstraZeneca vaccine significantly reduces health risks during the COVID-19 infection period.

Special Features

Full Text


Track Your Manuscript

Media Partners